MARKET

AKBA

AKBA

Akebia Therapeut
NASDAQ
0.9618
+0.0153
+1.62%
Opening 11:43 09/11 EDT
OPEN
0.9695
PREV CLOSE
0.9465
HIGH
0.9828
LOW
0.9595
VOLUME
3.34M
TURNOVER
--
52 WEEK HIGH
3.200
52 WEEK LOW
0.8140
MARKET CAP
266.52M
P/E (TTM)
-8.6649
1D
5D
1M
3M
1Y
5Y
1D
WestPark Capital Initiates Coverage of Akebia Therapeutics with Buy Rating
NASDAQ · 2d ago
Akebia Therapeutics Price Target Announced at $4.50/Share by WestPark Capital
Dow Jones · 3d ago
WestPark Capital Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $4.5
Benzinga · 3d ago
Akebia initiated with a Buy at WestPark Capital
TipRanks · 3d ago
Weekly Report: what happened at AKBA last week (0831-0904)?
Weekly Report · 4d ago
Akebia’s Vadadustat Trial Nears Data Readout, Raising Stakes in Dialysis Anemia Market
TipRanks · 09/04 16:30
Weekly Report: what happened at AKBA last week (0824-0828)?
Weekly Report · 08/31 09:44
Weekly Report: what happened at AKBA last week (0817-0821)?
Weekly Report · 08/24 09:44
More
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). The Company's development pipeline includes mid-stage rare kidney disease pipeline assets (praliciguat and AKB-097) and early-stage pipeline assets (AKB-9090 and AKB-10108), which are HIF molecules.

Webull offers Akebia Therapeutics Inc stock information, including NASDAQ: AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.